Binghamton University Leads Global Brain Cancer Research Accelerator

A growing international program, guided by the expertise of Binghamton University’s School of Pharmacy and Pharmaceutical Sciences, is accelerating the development of latest therapies for brain cancer. The Brain Tumour Research Novel Therapeutics Accelerator (BTR-NTA) aims to bridge a critical gap in the translation of promising research into viable clinical trials, offering hope for patients facing a particularly challenging diagnosis.

Brain tumors are notoriously difficult to treat, and in the last 40 years, almost no new treatments have emerged, with life expectancy after diagnosis remaining at just 12-18 months. Historically, clinical trials have often failed to deliver meaningful improvements for patients. The BTR-NTA, launched under the Tessa Jowell Brain Cancer Mission (TJBCM) in 2023, seeks to change this trajectory by providing expert guidance to researchers in both academic and industry settings.

Navigating the Complex Path to Clinical Trials

The program, spearheaded by Kanneboyina Nagaraju, Dean of Binghamton University’s School of Pharmacy and Pharmaceutical Sciences, operates on a model similar to the successful TREAT-NMD Advisory Committee for Therapeutics (TACT) in the neuromuscular field. The TJBCM identified the neuromuscular community’s progress – achieving new treatments and improved patient outcomes over the last 15 years – as a potential blueprint for accelerating brain tumor research. “What struck me about the neuromuscular community…is that in the last 15 years, they managed to approve new treatments and improve outcomes for their patients, and I felt that as a brain tumor community, we could learn from them,” explains Nicky Huskens, CEO of TJBCM. Learn more about the BTR-NTA.

Developing new therapies is rarely straightforward. Researchers face complex hurdles related to safety, clinical trial design, navigating regulatory requirements, and securing commercialization pathways. The BTR-NTA provides a structured framework to address these challenges, offering expert evaluation and guidance at each stage. Since its launch, the program has reviewed 19 therapies from 33 international groups (55% academic, 45% industry). Notably, 100% of applicants have secured follow-on funding from foundations, government bodies, or investors, and two have already progressed to human trials.

A Focus on Rare Diseases and Ethical Considerations

Nagaraju’s dedication to rare diseases, inspired by a quote from William Harvey – “Nature is nowhere accustomed more openly to display her secret mysteries than in cases where she shows tracings of her workings apart from the beaten paths” – underscores the program’s commitment to addressing unmet medical needs. He believes that research into rare diseases often reveals fundamental biological principles that might otherwise remain hidden. Binghamton University News details Nagaraju’s long-standing focus on rare conditions.

This commitment extends to an ethical dimension, recognizing that therapies shouldn’t be judged solely on commercial potential. “Suffering is suffering – whether a disease affects millions of people or only a few thousand,” Nagaraju emphasizes. “Patients should never be left without hope simply because their disease is not considered profitable.” This principle guides the BTR-NTA’s evaluation process, ensuring that promising therapies for even rare brain tumor subtypes receive consideration.

How the BTR-NTA Works: A Collaborative Approach

The BTR-NTA operates as an international advisory committee, drawing on expertise from within and outside the brain tumor field. Applicants submit their research for review, and the committee evaluates the experimental evidence, patent status, regulatory interactions, and future plans. The program is free for academic researchers and available at a nominal cost for industry applicants.

Successful applicants gain access to a day-long intensive session with 15 world-class drug development experts. This includes guidance from regulatory specialists, clinicians, scientists, and professionals with commercial funding experience. Following the session, applicants receive a detailed report outlining recommendations for optimizing their treatment’s path to success. The program aims to foster a collaborative research culture, promoting growth not only for applicants but as well for the committee members involved.

Building on the Neuromuscular Model

The BTR-NTA’s structure is directly inspired by the TACT model, which has demonstrably improved outcomes in the neuromuscular field. TACT’s success stemmed from its ability to navigate the complexities of translational research, and the TJBCM sought to replicate this approach for brain tumors. Google News reports on Binghamton University’s role in this international effort.

The core goal is to support companies in successfully delivering treatments to patients. This support involves a thorough evaluation of the team’s experimental evidence and progress, ensuring that future plans are optimized for the best possible chance of success. The BTR-NTA’s holistic approach, encompassing scientific, regulatory, and commercial considerations, sets it apart and positions it as a vital resource for brain tumor research.

Looking Ahead: Fostering a Thriving Research Ecosystem

Huskens and Nagaraju share a common vision for the BTR-NTA: to create a thriving research ecosystem that not only accelerates the development of new therapies but also fosters continuous learning and improvement within the brain tumor community. Huskens’ short-term goal is for all applicants and committee members to find the program a worthwhile educational experience, enhancing their drug development skills collectively.

The long-term aspiration is even more ambitious: to see BTR-NTA alumni successfully develop new treatments, ultimately leading to longer lives and improved quality of life for patients with brain tumors. The program’s commitment to addressing rare diseases, coupled with its collaborative and ethically driven approach, offers a beacon of hope in a field that has long faced significant challenges. The BTR-NTA represents a significant step forward in the fight against brain cancer, driven by the dedication of researchers at Binghamton University and partners around the globe.

For researchers interested in applying to the BTR-NTA, or learning more about the program, visit the Tessa Jowell Brain Cancer Mission website.